Please assess the completion status of the following clinical trial:

Trial Title: Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Non-metastatic biopsy-proven clear cell renal cell carcinoma (T2-T3N0-1M0)~* Schedule to undergo either partial or radical nephrectomy as part of treatment plan~* ECOG performance status of 0 or 1~* Adequate organ and marrow function defined by study-specified laboratory tests~* Agree to comply with scheduled visits, treatment plans, lab tests and other study procedures~* Do not have any other cancers in the 5 yr preceding diagnosis of their renal cancer~Exclusion Criteria:~* Patients who have received other systems for anti-tumor treatment~* Patients who have previously received targeted or immunotherapy~* Need for urgent or emergent nephrectomy to relieve symptoms~* Current use of immunosuppressive agents~* Pregnant or breastfeeding women~* History of autoimmune disease or syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Neoadjuvant arm (Type: EXPERIMENTAL): Patients will receive axitinib 5 mg bid combined with Toripalimab 3mg/KG q3w for up to 12 wk.

Based on this trial design, predict the completion outcome and termination type (if applicable).